Decode emerges from bankruptcy with new focus

Iceland-based genetics company DeCode Genetics has emerged from bankruptcy and says it will focus its efforts on genetic research and gene-based diagnostics. It's walking away from the drug development business. Decode release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.